How about Doderer, Jabbour, Krishna Kowlgi, Toshi Ando and

New Post Public Reply Private Reply Replies (0) Message Board
Puravida19 TedJ #14894
438
How about Doderer, Jabbour, Krishna Kowlgi, Toshi Ando and yes the lab techs. Or have they all left the company?

///answer: on LinkedIn Doderer is VP of r&d and Jabbour is CSO and BoD but is employed by U of Ottawa and the Canadian NRC. Kowlgi has always worked for TSU and might have consulted for QMC. Ando-San is now a consultant. Do you know who is doing what now? The company has not said and neither have the people you mentioned and your guess is as good as mine. If you think they are working for QMC, on projects other than blockchain, I would say it's possible it integrates blockchain into whatever they are working on because that is the path corporate and state businesses are taking these days. I'm not saying that, so don't misquote me please.
///

The only recent departures that I know of were Hartigan and Mcginniss, both health/software guys.

So QMC has a shelf full of ready to go QD products that they are just waiting for buyers to show up and buy? No ongoing internal R&D to make them better or expand the portfolio? No effort to actually sell any of these QD products or to sign a JV?

//)answer: You know QMC makes the best
QD and nanocrystals and nanoparticles.
Anyone can read the PRs and understand the how and why. It's not debatable, it's a fact. What Squires has said is QMC should be paid the value of the QD in whatever product a manufacturer wants to make, Some sort of JV and licensing and royalties accomplishes that goal and he has stuck to this principle. That's the business plan.

There is no need for further R&D on their QD, which are the best now because they have the best brightness or whatever technical term you want to insert there, and they are environmentally resistant to air, heat and moisture and can be mass produced in any quantity. It's a near perfect QD, and it's ready for commercialization.

In simple terms, a JV involving QD would need QMC to manufacture a specific QD. Years ago I posted a list of over 20 QD and nanocrystals they could make and had listed in their online store at the time. So the QD are not a problem for type or quality or quantity.

The other parts of the JV are:
1. working capital; Investment
2. Factory; place of manufacturer
3. The IP; Patented technology
4. Development and License and royalties to QMC. Other profits generated are the partner's. It's a fair deal. It's not QMC'S fault if they turn down deals that don't fit the parameters of the business plan, if that's what happened. Instead I see Squires learning from each deal experience and evolving and improving.

The JV partner is responsible for 1 to 4.
///


“If course, I expect Assam researchers are already working at the minimum on PPE related projects since I believe at least one reactor is up and running. Other QD applications are possibly being worked on.”

When I listen to the AMTRON Foundation Day video (https://www.youtube.com/watch?v=Ei4Mn_YIgXM&t=1299s) , I hear a lot about AMTRON’s main mission, providing internet and IT services to the State of Assam, and a remote possibility that they could start up one of the reactors and produce nanoparticles to be provided to others for possible PPE applications. Just produce a commodity that others may be able to use to produce a product. No research by AMTRON to discover new QD applications.

In the video, I saw a bigger need for AMTRON to fulfill its IT mission by providing IT services to the Indian health services, schools, government, businesses and the people of Assam, rather than exploring new business opportunities.

///answer: The main mission of AMTRON is providing state services in IT and building business through economic development. I remind you that QMC'S Licencee is the Anchor Tenant for the Electronics Manufacturing Complex, and the plan is to build a now estimated 75,000 SQ ft factory for them. That's big!

But there is a big misunderstanding if you think a building is necessary to get QD production started. All that's needed is one or two small labs for the reactor, it could be placed in the India-reknown Nanotech University connected to the eminent IITG.
Best of all the reactors are automated and software controlled so once setup, operations are teachable IMO. Its not easy to get into IITG, so no doubt they can easily handle the work.///

First AMTRON would need QMC to remotely set up the reactor and then teach AMTRON how to produce nanoparticles. If this could be done so AMTRON could produce and sell gold nanoparticles to PPE manufacturers in India, then why hasn’t QMC been producing nanoparticles in San Marco since April and selling them in the U.S. or to India? Maybe not a high margin commodity, but a saleable product to keep the wet lab reactors up and running and a great PR opportunity for QMC in the midst of the Covid crisis, while QDXH was bringing the App to market.

///answer: mostly already answered above. I will just summarize that QMC has no reason to produce QD without paid clients. The results of QMC'S tests on its QD or samples would be subject to NDA and or contacts, and we know that right now QMC is a non-reporting Pink with no obligation to report stages of progress, especially because I think it is generally agreed that revenue will move the stock.///

I don’t buy the idea that the Indian IT people have been spending the last three months developing new QDs or new QD applications. I don’t think that they have the time, the money, or other resources to do it.

///answer: First, it's not that the PPE IP is new, it's actually all over the internet these days. The ability to manufacture the best nanomaterials, with high quantity and quality, in a JV, where the QD are contributed to the project to lower the startup cost to presumably a clothing manufacturer with an idle factory that can attract investors, and where there are India government programs for this, is what's new. Think bigger, my friend. Squires is not limited by your expectations of puny QD sales.///

Quantum Materials Corp. (QTMM) Stock Research Links

QTMM Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 307

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 211

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 246

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 694

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 63

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 351

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 239

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 105

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 27

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 180

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading

Top 5 Most Recently Viewed Articles

HD Hyundai Sparks Fusion Hopes with ITER Milestone

Updated Category News Views 9

Hold on to Your Hard Hats, Fusion Milestone Achieved Look who's making waves in the world of nuclear fusion. HD Hyundai Heavy Industries has hit a crucial benchmark in the ITER nuclear fusion project. This ain't your run-of-the-mill accomplishment, folks. We're talking about completing the assembly of some of the most complex and intricately designed machinery known to...

Continue Reading
ChemoMetec Boosts Financial Outlook with Anticipated Growth

Updated Category News Views 353

ChemoMetec Boosts Financial Outlook Amid Growing Interest ChemoMetec is excited to announce an upgrade in its financial guidance as the company sees a growing demand for its pioneering technologies, particularly the highly regarded XcytoMatic platform. This surge in interest bodes well for the company's revenue and profit, reflecting a positive trajectory as it approaches...

Continue Reading
GDS Holdings Completes Successful C-REIT IPO on Shanghai Exchange

Updated Category News Views 200

GDS Holdings Limited Celebrates C-REIT IPO Success GDS Holdings Limited, known as GDS, is thrilled to announce that it has successfully completed its initial public offering of its China REIT, or C-REIT, on the Shanghai Stock Exchange. This milestone marks an exciting moment for the company and its stakeholders as market interest surpassed expectations. Highlighting the...

Continue Reading
Innovative E-Waste Solutions from Techbros Redefine Recycling

Updated Category News Views 273

AI-Driven E-Waste Innovation from Techbros In a remarkable leap towards sustainability and innovative technology, Techbros Electronic Recycling proudly announces the launch of the Southwest's first fully integrated AI-driven IT asset disposition (ITAD) and e-waste processing facility. This state-of-the-art facility exemplifies the future of electronics recycling by...

Continue Reading
SageSure Welcomes Insurance Veteran Peter Hearn to Board

Updated Category News Views 268

SageSure Welcomes New Board Member SageSure, one of the largest managing general underwriters that focus on markets exposed to catastrophe risks, has taken a significant step by appointing Peter Hearn to its Board of Managers. This strategic move is anticipated to bolster the company’s leadership and industry insights. Peter Hearn's Impressive Background Peter Hearn...

Continue Reading